You keep asking “What’s BKTH going to sell?” which tells me you still don’t understand what the company actually is. BKTH isn’t a retail product outfit — it owns multiple engineered chemistry platforms with real IP, real formulations, and real licensing pathways. Nothing here is something you “buy from a distributor.” That’s why partners license the tech instead of grabbing commodity chemicals.
The CITR deal is the perfect example: they licensed specific BKTH IP and blends in a structured $1.8M agreement. Nobody pays seven figures for something “anyone can buy.”
As for APAC — there’s no “APAC website” because APAC isn’t a product brand. It’s an agency footprint. Interway handles licensing, banking, onboarding, and regional deployment. Agencies don’t build storefronts.
And the “smell test” about volume? BKTH hasn’t run IR, hasn’t promoted, hasn’t marketed, hasn’t pushed liquidity. Low volume reflects zero awareness, not “no deal.” The only people worried about liquidity are the ones trying to exit — and judging by the board, that’s basically nobody. A few people complain, but nobody’s actually leaving.
BKTH is the real deal.
The only thing missing is visibility — not substance.
But since you’re so focused on “smell tests,” maybe ask yourself a better one:
How’s Blagman and MWWC doing these days? Blagmans Business Eulogy pretty much sums it up !
NEXT
Market Data 
Markets 
